Evidence map›Paper›PMID 39722591›Full record

ArticleHead & neck2025

Locked Dimerized CXCL12 Exerts Radiosensitizing Effects in Head and Neck Cancer.

Oscar Villarreal Espinosa, Musaddiq Awan, Abdullah A Memon, Anne Frei, Jamie Foeckler, Rachel Kuehn, Jennifer Bruening, Becky Massey, Stuart Wong, Monica Shukla and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Oscar Villarreal EspinosaMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Musaddiq AwanCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Abdullah A MemonMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Anne FreiCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jamie FoecklerCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Rachel KuehnMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jennifer BrueningCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Becky MasseyCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Stuart WongCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Monica ShuklaCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Julia KasprzakCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Amit JoshiCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Michael B DwinellCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Heather A HimburgCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0002-9676-6371
Joseph ZengaCancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Funding

IVIS Spectrum CT imager for the Medical College of WisconsinS10OD032237 · OD · MEDICAL COLLEGE OF WISCONSIN · PI JOSHI, AMIT · 2022 to 2022
$599k
Determining the role of the SDF-1/CXCR4 pathway and its intersection with chronic stress to establish novel precision approaches to head and neck cancer managementR21CA279935 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI ZENGA, JOSEPH · 2023 to 2024
$392k
Don and Sharyn Blatnik Endowment at the Medical College of WisconsinMedical College of Wisconsin Cancer CenterMedical College of Wisconsin Department of Radiation OncologyNCI NIH HHS (R01 CA226279)NCI NIH HHS R21 CA279935NIH HHS S10 OD032237
6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) presents significant treatment challenges, particularly in cases unrelated to human papillomavirus (HPV). The chemokine receptor CXCR4, interacting with its ligand CXCL12, plays a crucial role in tumor proliferation, metastasis, and treatment resistance. This study explores the therapeutic potential of engineered monomeric and dimerized CXCL12 variants (CXCL12

methodsClinical HNSCC biopsies were evaluated for CXCR4 expression in both previously untreated and radiorecurrent disease. HNSCC cell lines were then treated with combinations of CXCL12 variants and radiotherapy and interrogated for proliferation, gene expression change, and underlying molecular mechanisms. In vivo studies evaluated the biodistribution of engineered CXCL12 and tested these treatments in humanized cell line-derived xenograft (CDX) models.

resultsCXCL12

conclusionsCXCL12

Indexed as

Carcinoma, Squamous CellChemokine CXCL12Head and Neck NeoplasmsRadiation-Sensitizing AgentsSquamous Cell Carcinoma of Head and NeckAnimalsCell Line, TumorCell ProliferationFemaleHumansMaleMiceReceptors, CXCR4Xenograft Model Antitumor AssaysChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanRadiation-Sensitizing AgentsReceptors, CXCR4chemokineCXCL12CXCR4head and neck cancermolecular oncology

Identifiers

PMID39722591
PMCPMC12040585

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.